Last reviewed · How we verify
Staphylococcus Aureus Complicated UTI — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Vantobra | Tobramycin Sulfate | Pfizer | tobramycin | Taste receptor type 2 member 20 | 1974-01-01 | |
| Tobi | tobramycin | Novartis | Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) | |||
| Nebcin | Nebcin | University Hospital, Lille | Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Staphylococcus Aureus Complicated UTI
- Novartis · 1 drug in Staphylococcus Aureus Complicated UTI
- Pfizer · 1 drug in Staphylococcus Aureus Complicated UTI
- University Hospital, Lille · 1 drug in Staphylococcus Aureus Complicated UTI
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Staphylococcus Aureus Complicated UTI:
- Staphylococcus Aureus Complicated UTI treatment updates — RSS
- Staphylococcus Aureus Complicated UTI treatment updates — Atom
- Staphylococcus Aureus Complicated UTI treatment updates — JSON
Cite this brief
Drug Landscape (2026). Staphylococcus Aureus Complicated UTI — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcus-aureus-complicated-uti. Accessed 2026-06-10.
Related
- Staphylococcus Aureus Complicated UTI full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing